InflaRx N.V. (IFRX) InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
InflaRx N.V. NASDAQ:IFRX Healthcare · Biotechnology
Mkt Cap $244.63M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
InflaRx Announces November Investor Events
InflaRx announced its November events calendar, including conference appearances at the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference.
The company will report Q3 2026 results on November 3 before market open via a Form 6-K, the same day as its previously announced virtual Capital Markets Day focused on izicopan in ANCA-associated vasculitis.
No financial results or new clinical data were disclosed in this release; it is a scheduling notice only.
• 5d ago AI analysis › Press Release ⚠ 2
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
InflaRx presented new pre-clinical data on oral C5aR1 antagonist izicopan at ASN Kidney Week 2026, showing renal protection in two hamster models of kidney injury.
In both ischemia-reperfusion injury and obstructive nephropathy models, izicopan significantly reduced markers of renal injury (BUN and creatinine, p < 0.001) versus vehicle controls.
Structural modeling suggests izicopan avoids the CYP3A4/5 time-dependent inhibition seen with avacopan, supporting a differentiated, potentially best-in-class profile. The company is advancing izicopan toward development in ANCA-associated vasculitis and additional renal indications.
• 10d ago AI analysis › Press Release
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx was selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026 in Denver, presenting data on izicopan in kidney disease models.
Izicopan is an oral second-generation C5aR1 antagonist that achieved ≥90% blockade of C5a-induced neutrophil activation over 14 days and was well tolerated in first-in-human and Phase 2a testing, including in hidradenitis suppurativa and chronic spontaneous urticaria.
The company is planning development of izicopan in ANCA-associated vasculitis and additional renal indications; the poster itself recaps existing data rather than disclosing new results.
• 0mo ago AI analysis › Press Release
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
InflaRx appointed Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.
She joins from CSL Vifor, where she led cardiovascular and renal clinical development, with over 20 years of experience across CSL Vifor, AbbVie and Bristol-Myers Squibb including Phase 2/3 registrational programs in renal indications.
Her renal and complement-disease background aligns with InflaRx's plan to advance izicopan into ANCA-associated vasculitis and additional renal indications.
• 1mo ago AI analysis › Press Release ⚠ 1
InflaRx to Host Virtual Capital Markets Day
InflaRx N.V. (Nasdaq: IFRX) will host a virtual Capital Markets Event on November 3, 2026, running from 8:00 AM EST to approximately 9:00 AM EST, with pre-registration required for access.
The timing was shifted to better accommodate scheduling and the company's clinical development planning processes in ANCA-associated vasculitis, where its oral C5aR inhibitor izicopan is being positioned to improve on the existing standard of care.
Featured speakers include vasculitis expert Dr. Peter A. Merkel of the University of Pennsylvania and complement biologist Prof. Dr. Jörg Köhl of the University of Lübeck, alongside InflaRx management, with a question-and-answer session to follow.
• 1mo ago AI analysis › Press Release
InflaRx Announces Participation in September Investor Conferences
InflaRx N.V. announced it will participate in the Cantor Global Healthcare Conference in New York on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14.
Management is scheduled to conduct fireside chats and presentations, with one-on-one investor meetings also planned at both events.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system, with its lead oral small molecule candidate izicopan in clinical studies for ANCA-associated vasculitis.
• 2mo ago AI analysis › Press Release
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
InflaRx reported Q2 2026 results with a fortified balance sheet, ending the period with €158.4 million in total funds which management projects will support operations into 2029.
The company is advancing its lead oral asset izicopan, initiating Phase 2 planning for ANCA-associated vasculitis and targeting select renal diseases, while engaging with European regulators to potentially fill the market void left by Tavneos.
Net losses narrowed to €16.2 million from €22.7 million year-over-year, supported by a €119.3 million net capital raise completed in May at $2.00 per share.
• 2mo ago AI analysis › Press Release ⚠ 1
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V. announced that it will release its second quarter 2026 financial and operating results before the market opens on August 6, 2026.
The company noted that no conference call is planned to accompany the earnings release.
• 3mo ago AI analysis › Press Release ⚠ 1
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx is assessing the feasibility of broadening its European strategy for ANCA-associated vasculitis (AAV) following the EMA's recommendation to revoke marketing authorization for competitor drug Tavneos.
The company plans to engage with regulators regarding both vilobelimab and izicopan to determine the most efficient development path for these C5a/C5aR inhibitors in the AAV indication.
Management stated that vilobelimab is a Phase 3-ready asset in AAV, while Phase 2 planning for izicopan continues uninterrupted across multiple geographies.
• 4mo ago AI analysis › Press Release ● Major ⚠ 2
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has completed a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share.
The proceeds will be used to advance the company's pipeline activities, including the development of izicopan and vilobelimab, as well as for working capital and general corporate purposes.
The offering included participation from new and existing investors, with Guggenheim Securities acting as the lead bookrunner and several other firms participating as underwriters and co-managers.
• 5mo ago AI analysis › Press Release ● Major ⚠ 1
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx priced a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share.
The company is selling all shares in the offering and intends to use the net proceeds for pipeline activities as well as working capital and general corporate purposes.
The financing received participation from new and existing investors, including TCGX and Farallon Capital Management, with Guggenheim Securities acting as lead bookrunner.
• 5mo ago AI analysis › Press Release
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx announced a strategic advancement of its oral C5aR inhibitor izicopan into ANCA-associated vasculitis (AAV), with Phase 2 planning underway and an eye toward an expedited regulatory path.
The company also intends to establish rapid proof of concept in other renal diseases including aHUS, IgAN, and C3G, with open-label studies expected to generate data next year.
Management estimates that current funds are sufficient to support planned development and operations through 2029, extending the runway significantly.
• 5mo ago AI analysis › Press Release
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx reported pre-clinical data showing izicopan demonstrated minimal reactive metabolite formation in human liver microsomes, suggesting a lower bioactivation risk compared to the marketed drug avacopan.
In the head-to-head in vitro study, izicopan showed lower levels of thiol adducts than avacopan, with differences exceeding 100-fold at early time points, supporting a differentiated profile for the oral C5aR1 inhibitor.
While these in vitro findings do not directly predict clinical outcomes, the company believes they support the potential safety and differentiation of izicopan.
• 5mo ago AI analysis › Press Release ● Major
InflaRx to Report First Quarter 2026 Results on May 7, 2026
globenewswire.com • 6mo ago Press Release
iFOREX Lists on London Stock Exchange, Supporting Focus Across Global and Indian Markets
iFOREX has admitted to the Main Market of the London Stock Exchange under ticker IFRX, achieving a market valuation of approximately £43.3 million.
The listing is designed to support the company's global growth strategy, with a specific emphasis on expanding its presence in the Indian market.
Leveraging over 30 years of experience, iFOREX provides access to more than 900 financial instruments via proprietary web and mobile platforms.
• 6mo ago AI analysis › Press Release
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx N.V. received notice from Nasdaq that it has regained compliance with the exchange's minimum bid price requirement.
The company met the rule by maintaining a closing bid price of at least $1.00 for 10 consecutive business days between April 13 and April 24, 2026.
The biopharmaceutical firm continues to focus on its pipeline, including the oral inhibitor izicopan and the anti-C5a antibody vilobelimab.
• 6mo ago AI analysis › Press Release
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
globenewswire.com • 6mo ago 
